What is ResMed's market cap?

ResMed (RMD) has a market capitalization of $29.9B and trades on NYSE.

What is ResMed's revenue and profitability?

ResMed generated $5.5B in trailing twelve-month revenue with net income of $1.5B, representing a net margin of 27.4%. Gross margin stands at 61.6%, with free cash flow of $1.8B. These figures are based on the Q1 2026 filing.

Who are ResMed's competitors?

ResMed's key competitors include Koninklijke Philips N.V., Fisher & Paykel Healthcare, Inspire Medical Systems, and others. These companies compete in similar markets and product categories.

Who does ResMed partner with?

ResMed's notable partners include Alphabet Inc..

What subsidiaries does ResMed have?

ResMed's subsidiaries include Brightree, MatrixCare, Propeller Health.

Where is ResMed headquartered?

ResMed is headquartered in United States of America and employs approximately 10,140 people. It has been publicly traded since 1995.

ResMed

RMD

ResMed is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the healthcare market.

Market cap

$29.86B-20.8%

Revenue$5.5B+10.3%

Net income$1.5B+15.7%

Free cash flow$1.8B+11.8%

EPS (diluted)$10.37+16.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q3 2026 report

April 30, 2026

Revenue$1.4BBeat by $11.5M EPS$2.86Beat by $0.07

Read the full report

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$1.5B

EPS estimate$2.90

Financials

Q3 2026

Income statement

See full

Revenue$1.4B+10.8%

Gross profit$891.0M+16.3%

Operating income$499.8M+17.3%

Net income$398.7M+9.2%

EPS (diluted)$2.74+10.5%

Balance sheet

See full

Cash & equivalents$1.7B+78.0%

Total debt$1.1B+29.8%

Total equity$6.5B+17.1%

Total assets$8.8B+16.1%

Cash flow

See full

Operating cash flow$554.1M-4.2%

CapEx$33.7M+61.8%

Free cash flow$520.5M-6.7%

Valuation & ratios

Valuation

See full

Market cap$29.86B-20.8%

Enterprise value$29.3B-21.5%

P/E19.7×-7.2×

P/S5.4×-1.9×

Profitability

See full

Gross margin61.6%+2.8pp

Operating margin34.2%+2.1pp

Net margin27.4%+1.3pp

FCF margin31.7%+0.4pp

Returns & leverage

See full

Return on equity25.2%-0.6pp

Debt / equity0.2×0.0×

Current ratio3×-0.4×

Segments

By product

See full

Devices$1.5B+8.8%

Sleep And Breathing Health$1.3B+11.5%

Masks and other$1.0B+15.5%

Residential Care Software$170.9M+6.0%

By geography

See full

Global revenue$1.4B+10.8%

U.S., Canada and Latin America$818.7M+9.3%

Combined Europe, Asia and other markets$441.8M+15.9%

By segment

See full

Sleep and Breathing Health$1.3B+11.5%

Residential Care Software$170.9M+6.0%

Competitors

By market cap

Eli Lilly$1.08T+54.7%

ResMed$29.9B-20.8%

Philips$26.8B+19.9%

LivaNova$4.5B+80.2%

Inspire Medical Systems$1.4B-62.5%

Viemed Healthcare, Inc.$465.4M+64.7%

Five Point Holdings, Inc.$370.1M-8.1%

Vivos Therapeutics, Inc.$6.7M-74.4%

By revenue growth

Eli Lilly+47.4%

Viemed Healthcare, Inc.+23.1%

LivaNova+12.4%

ResMed+10.3%

Inspire Medical Systems+8.9%

Five Point Holdings, Inc.-54.2%

By net margin

Five Point Holdings, Inc.41.16%+4.1pp

Eli Lilly34.99%+12.3pp

ResMed27.44%+1.3pp

Inspire Medical Systems14.33%+6.4pp

Viemed Healthcare, Inc.5.2%-0.1pp

LivaNova-16.12%-22.5pp

Profile

ResMed is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the healthcare market. The company primarily focuses on the treatment and management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases. Its value proposition centers on improving patient outcomes and provider efficiency through connected health technologies and data-driven respiratory care.

Competitive position

ResMed is a dominant global player in the sleep apnea market, characterized by high R&D investment and a massive installed base of cloud-connected devices.

GeographiesNorth America, Europe, Asia-Pacific, Latin America

Customer segmentsHealthcare Providers, Medical Equipment Distributors, Chronic Disease Patients

Business modelManufacturing, Subscription SaaS, B2B, Direct-to-Consumer

SuppliersElectronic component manufacturers, Medical-grade plastic suppliers, Cloud infrastructure providers, Logistics and freight services

CustomersSleep diagnostic centers, Home medical equipment (HME) providers, Third-party payors, Retail pharmacies

CountryUnited States of America

Listed1995

Employees10.1K

CEOMichael J. Farrell

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websiteresmed.com

FilingsSEC EDGAR

Ask your AI about ResMed.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ResMed's market cap?: ResMed (RMD) has a market capitalization of $29.9B and trades on NYSE.
What is ResMed's revenue and profitability?: ResMed generated $5.5B in trailing twelve-month revenue with net income of $1.5B, representing a net margin of 27.4%. Gross margin stands at 61.6%, with free cash flow of $1.8B. These figures are based on the Q1 2026 filing.
Who are ResMed's competitors?: ResMed's key competitors include Koninklijke Philips N.V., Fisher & Paykel Healthcare, Inspire Medical Systems, and others. These companies compete in similar markets and product categories.
Who does ResMed partner with?: ResMed's notable partners include Alphabet Inc..
What subsidiaries does ResMed have?: ResMed's subsidiaries include Brightree, MatrixCare, Propeller Health.
Where is ResMed headquartered?: ResMed is headquartered in United States of America and employs approximately 10,140 people. It has been publicly traded since 1995.